Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway

Ilio Vitale1,2,3, Lorenzo Galluzzi1,2,3, Sonia Vivet1,2,3, Lisa Nanty1,2, Philippe Dessen2,3,4,5, Laura Senovilla1,2,3, Ken A. Olausson1,2,3, Vladimir Lazar1,4,5, Michelle Prudhomme6, Roy M. Golsteyn7, Maria Castedo1,2,3, Aubière, France, mitosis, p53 activation and Puma/BBC3-dependent mitochondrial apoptosis. Altogether, our results demonstrate that, in tetraploid tumor cells, the inhibition of Chk1 sequentially triggers aberrant Chk1 inhibition activated p53-regulated transcripts including Puma/BBC3 in tetraploid but not in diploid tumor cells.

Université Blaise Pascal, Synthèse et Étude de Systèmes à Intérêt Biologique, UMR 6504 Centre National de la Recherche Scientifique (CNRS), Villejuif, France, National de la Recherche Scientifique (CNRS), FRE2939, Villejuif, France, Université Blaise Pascal, Synthèse et Etude de Systèmes à Intérêt Biologique, UMR 6504 Centre National de la Recherche Scientifique (CNRS), Aubière, France, 7 Institut de Recherche Servier, Croissy sur Seine, France

INTRODUCTION

Cancer results from the accumulation of genetic and epigenetic alterations in which genomic instability conditions the progressive deterioration towards an ever more aggressive phenotype. One of the mechanisms of genomic instability involves a transient phase of polyploidization (in most cases tetraploidization), which may result from endoreplication (DNA replication without mitosis), endomitosis (karyokinesis without cytokinesis) [1] or aberrant cell fusion [2,3]. Tetraploid cells then can undergo asymmetric cell division and/or chromosome loss, leading to aneuploidization and chromosomal instability [4–6].

Under normal conditions, a variety of endogenous tumor suppressor gene products prevent the generation of tetraploid cells. For instance, p53 is activated immediately after illicit tetraploidization induced either by fusion [7], endoreplication, or endomitosis [8], and promote cell cycle arrest [9–12] and/or the activation of pro-apoptotic genes that cause the elimination of the tetraploid cell by programmed cell death [7,8,12,13]. Inactivation of the p53 pathway is hence permissive for tetraploidization [6]. Similarly, the loss of the tumor suppressor proteins p21 [14], Bax [8], APC [15], or Lats2 [12] facilitates the generation of tetraploid cells. Symmetrically, overexpression of oncogene products such as Aurora kinase A [16] or papillomavirus E6 [17] induces tetraploidization. One possible interpretation of these findings is that a hypothetical “tetraploidy checkpoint” [9] would prevent the generation or propagation of tetraploid cells, by mean of a stable cell cycle arrest or their elimination by apoptosis. Indeed, defective checkpoints have been involved in oncogenesis, at several levels. As an example, it has been shown that the activation of Chk2 helps in the elimination of potentially malignant cells [18,19], and that familial loss-of-function mutations [20] or an acquired interruption of Chk2 activation [18,19] contribute to oncogenesis. The checkpoint kinase-1 (Chk1) is also lost in aggressive lymphoid tumors [20]. Nonetheless, Chk1 is involved not only in tumor suppression, and its inhibition can sensitize tumor cells to DNA damage [21–24], presumably because the failure to arrest the cell cycle upon DNA damage is a lethal event.

Experimental tetraploidization of p53-negative mammary epithelial cells can be employed as a method to generate transformed, tumorigenic cells, thus providing a proof-of-principle that tetraploidization may constitute an important intermediate step in carcinogenesis [5]. Heterotypic fusion has been described in vivo, in rodent models, for instance between tumor cells and infiltrating cells from myeloid origin [25] and may contribute to the plasticity of cancer. A fusogenic retrovirus can induce the transformation of human cells in vitro through cell fusion [26]. Accordingly, pre-malignant and malignant tetraploid cells have been documented in precancerous lesions such as Barrett’s esophagus [27], in pre-invasive lesions of the uterine cervix [17,28], in laryngeal dysplasia [29], and in chronic ulcerative colitis dysplasia [30]. The presence of sub-clones of tetraploid/octoploid cells in human tumors has been correlated with worse.

Citation: Vitale I, Galluzzi L, Vivet S, Nanty L, Dessen P, et al (2007) Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway. PLoS ONE 2(12): e1337. doi:10.1371/journal.pone.0001337

Academic Editor: Nils Cordes, Dresden University of Technology, Germany
Received August 5, 2007; Accepted November 16, 2007; Published December 26, 2007
Copyright: © 2007 Vitale et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: MC is supported by Association pour la Recherche sur le Cancer. GK is supported by Ligue Nationale contre le cancer, Institut National du Cancer (N’ PL06_086), European Community (Active p53 EC FP6 funding, RIGHT, Trans-Death, Death-Train, CHEMOREs), and Institut Gustave Roussy. The authors have declared that no competing interests exist.

* To whom correspondence should be addressed. E-mail: kroemer@igr.fr
† These authors contributed equally to this work.
prognosis, for instance in uterine cervix carcinoma [31], squamous cell carcinoma of the head and neck [32], and in poorly differentiated prostate carcinoma [33].

Tetraploid cells are intrinsically resistant against genotoxic stress mediated by ionizing irradiation or by genotoxic agents used for anti-cancer chemotherapy, including platinum compounds (such as cisplatin and oxaliplatin) and topoisomerase inhibitors (such as camptothecin) [8,25], meaning that tetraploid cells have a high chance to survive apoptosis-inducing regimes. Since polyplid tumor cells accumulate in particular areas of the cancerous lesion, for instance in areas of hypoxia [34], it can be speculated that tetraploid cells might contribute to chemotherapeutic failure.

Based on these considerations, we wondered whether it might be possible to design strategies for the destruction of tetraploid tumor cells. Here, we report that inhibition of one particular drugable kinase, Chk1, leads to the selective destruction of tetraploid cancer cells. In addition, we provide an exhaustive characterization of the pro-apoptotic signal transduction pathway elicited by Chk1 inhibition.

RESULTS

Aberrant mitoses of tetraploid cells with an intact spindle assembly checkpoint (SAC)

Recently, we have developed a panel of tetraploid HCT116 and RKO cell clones that bear exactly twice the normal chromosome content than their diploid precursors, yet lack any other discernible numeric or structural chromosomal aberration [8] [35]. Tetraploid tumor cells exhibit a slightly reduced growth rate, by about 10%, as compared to their diploid precursors [8], a finding that prompted us to investigate the rate and efficacy of mitoses. While there was no difference in the rate of mitotic events between diploid and tetraploid HCT116 cells, we found a significantly increased frequency of abnormal mitoses in tetraploid cells (Fig. 1). Such abnormal mitoses were characterized by misaligned chromosomes during metaphase, multipolar (mostly tri- or tetrapolar) metaphases, anaphase bridges and cytokinesis failure resulting into binucleation (Fig. 1A,C). Among tetraploid, apparently normal or aberrant metaphases were frequently characterized by the activation of the spindle assembly checkpoint (SAC), as indicated by the presence of BubR1 on kinetochores (Fig. 1B,C). Accordingly, SAC was intact in tetraploid cells, because, treatment with nocodazole or docetaxel induced similar percentages of mitotic arrested cells and cell death in tetraploid and diploid clones (Fig. S1). Videomicroscopy of the nuclear and cellular divisions of tetraploid cells transfected with a histone H2B-GFP fusion construct (which allows to visualize chromosomes in live cells) confirmed that 10 to 15% of tetraploid mitoses were aberrant (Videos S1, S2), while less than 3% of diploid mitoses were abnormal.

A fraction of tetraploid cells displayed an activating phosphorylation of p33 (detectable by immunofluorescence using an antibody that stains p53 phosphorylated on serine 15) within their nuclei, and these phospho-p53-positive cells were in most cases (approximately 80%) bi- or multi-nucleated and/or or contained micronuclei (Fig. 1D,E), suggesting that p53 activation resulted from mitotic failure. The large majority of mitoses (as discerned by the presence of mitotic figures after Hoechst 33342 staining) were phospho-p53-negative. Only in a small percentage of mitoses that bears features of imminent apoptosis (with clumpy chromatin condensation), p33 appears to be phosphorylated (not shown). In contrast normal interphases (G1, S or G2) were mostly (>99%) negative for phospho-p53. Only cells with abnormal nuclear morphologies manifested the p53 phosphorylation on Ser15.

The frequency of cells that activated a p33-inducible green fluorescent protein (GFP) construct was higher among tetraploid than among diploid cells (Fig. 1F,G). As an internal control that the p33-inducible GFP indeed detected an elevated p53-mediated transactivation, we found that inhibition of p33 either chemically (with cyclic pifithrin-α) or genetically (by transfection with a dominant-negative p33 mutant) inhibited the production of p33-inducible GFP in response to cisplatin down to the background level (Fig. 1G). Altogether, these results suggest that catastrophic mitoses are responsible for an enhanced activation of the p33 system in tetraploid cells.

Aberrant mitoses of tetraploid cells are exacerbated by Chk1 inhibition

In view of the apparent difficulty of tetraploid cells to successfully complete mitosis, we wondered whether these cells might rely more heavily on the cell cycle checkpoint kinase Chk1 than diploid cells. Transient transfection with a Chk1-specific small interfering RNA (siRNA) (Fig. 2A) caused a dramatic increase in aberrant mitoses of tetraploid cells (one third of all mitoses), resulting in delayed mitotic exit, apoptotic disintegration of both daughter cells after cytokinesis, formation of binucleated cells, multipolar mitoses, or apoptosis during or shortly after the metaphase (Fig. 2B,C,D and videos S3, S4, S5, S6, S7, S8). This correlated with premature mitoses, detectable as events in which the phosphorylation of histone H3 by mitotic kinases occurs in cells that have not duplicated their genome, and hence have less than 8N DNA content (Fig. 2E,F). The percentage of premature mitoses was not affected by preincubation with the pancaspase inhibitor Z-VAD.fmk (not shown). The increase in frequency of aberrant or premature mitoses induced by Chk1 inhibition was more pronounced among tetraploid than among diploid cells (Fig. 2A–F).

Chk1 inhibition abolished the spindle assembly checkpoint (SAC) and activates p53

The knockdown of Chk1 resulted in a complete abolition of SAC resulting in the failure to recruit BubR1 and Bub1 to kinetochores during the prometaphase and aberrant metaphases for diploid and tetraploid cells (Fig. 3A,B for tetraploid cells). Indeed, after Chk1 knockdown less than 30% of prometaphases and aberrant metaphases exhibited the localization of Bub or BubR1 to kinetochores, indicating abolition of SAC in more than 70% of the cells. The percentage of SAC inhibition, as detectable among aberrant metaphases, was similar in diploid and tetraploid cells (although the number of aberrant metaphases is much higher in tetraploid cells, see Fig. 1). Small interfering RNA (siRNA)-mediated depletion of Chk1 or its pharmacological inhibition by UCN-01 (7-hydroxyxaustrosporine) also resulted in the activating phosphorylation of p33, more frequently in tetraploid than in diploid cells (Fig. 3C). Similarly, the knockdown of the essential SAC proteins Bub1, BubR1, Mad2 or Aurora B induced the phosphorylation of p33 on serine 15, more so in tetraploid than in diploid cells (Fig. 3D,E). Taken together, these data indicate that Chk1 inhibition abolishes SAC, and that SAC inhibition exacerbates mitotic defects coupled to p33 activation in tetraploid tumor cells.

Chk1 inhibition kills tetraploid cells

In view of the mitotic or post-mitotic apoptosis induced by Chk1 depletion (Fig. 2A–C), we quantified the frequency of cell death induced by Chk1 inhibition by cytofluorometric methods. Simultaneous detection of dying cells (which exhibit a dissipated mitochondrial transmembrane potential, i.e. $\Delta W_{int}$, and hence a
reduced DiOC6(3) incorporation) and dead cells (which possess permeabilized plasma membranes and hence incorporate the vital dye propidium iodide, i.e. PI) revealed that depletion of Chk1 with either of two distinct siRNAs killed tetraploid HCT116 cells more efficiently than diploid cells. This effect was less pronounced when instead of Chk1, Chk2 was depleted (Fig. 4A,B). The downregulation of Chk1 was more efficient in inducing an apoptosis-associated DNA loss (sub-G1 DNA content, as determined by staining with DAPI) among tetraploid than among diploid cells (Fig. 4C,D). Similar results were obtained for another colon carcinoma cell line, namely RKO (Fig. S2 A) in thus far that Chk1 depletion was more efficient in killing tetraploid than diploid tumor cells.

Figure 1. Abnormal mitoses linked to p53 activation in tetraploid HCT116 cells. A. Abnormal mitoses. Tetraploid cells were stained to visualize chromosomes (Hoechst 33342, blue) and γ-tubulin (green). The arrow marks a misaligned chromosome. B. Activation of the spindle assembly checkpoint (SAC) in tetraploid mitoses. Cells are stained to visualize chromosomes (blue), centromeres (CENP-B, red) and the SAC protein BubR1 (green). The white color results from the overlap of the three fluorescence signals, indicating recruitment of BubR1 to centromeres. C. Quantitation of the data obtained in A and B, comparing diploid and tetraploid cells in three independent experiments (X±SEM). D, E. p53 phosphorylation linked to abnormal mitoses. Representative examples of tetraploid cells that show incomplete cytokinesis, binuclea- tion and micronuclea- tion coupled to p53 phosphorylation on serine 15 (detected by immunofluorescence staining) are shown in D and quantified in E. F, G. Evidence for transcriptional activation of p53 in tetraploid cells. Diploid or tetraploid cells were transfected with dsRed (red fluorescence), a p53-inducible GFP construct (green fluorescence), and either empty vector only, a plasmid encoding for wild type p53 or dominant-negative p53 (H175) and then cultured for 48 h in the absence or presence of the p53 inhibitor cyclic pifithrin-α. Cells were labeled with the vital stain DAPI and the frequency of transfected (dsRed-expressing) cells that express GFP was determined by cytofluorometry as shown in D for vector-only controls cultured in the absence of pifithrin. Representative results (X±SEM, n = 3) from three independent experiments are shown in E. Asterisks indicate significant (p<0.01) differences between diploid and tetraploid cells.

doi:10.1371/journal.pone.0001337.g001
Since we worried about possible off-target effects of the Chk1-specific siRNAs, we repeated the experiments using alternative methods of Chk1 inhibition. Transfection with a dominant-negative (DN) Chk1 mutant (Fig. 5A) or inhibition of Chk1 with UCN-01 or SD1825 (Fig. 5B–F) resulted in an enhanced mortality of tetraploid HCT116 cells, with little or no effects on diploid cell. Efficient cell death of tetraploid cells was confirmed in RKO cells after pharmacological inhibition of Chk1 (Fig. S2B). Moreover, alternative strategies to subvert SAC, by knockdown of Bub1, BubR1, Mad2 or Aurora B caused cell death much more efficiently in tetraploid than in diploid cancer cells (Fig. 5G, H).
Cell death induced by Chk1 inhibition was accompanied by the hallmarks of apoptosis such as nuclear DNA condensation (Fig. 2B), mitochondrial cytochrome c release, caspase-3 activation (Fig. 5D,E), and phosphatidylserine exposure (Fig. 5F). In conclusion, tetraploid cells die from apoptosis after catastrophic mitoses due to SAC inhibition.

Synergistic killing of tetraploid cells by cisplatin plus Chk1 inhibition

As compared to their diploid counterparts, tetraploid cancer cells are relatively resistant against DNA damaging agents including cisplatin, both in vitro (Ref. [8], Fig. 6A,B for HCT116 and Fig. S2 C for RKO) and in vivo (Fig. 6C,D). Although there was no difference in the growth tumors originating from diploid versus tetraploid HCT116 cells inoculated into immunodeficient mice (Fig. 6C), tetraploid tumors responded far less to chemotherapy with cisplatin than diploid cancers (Fig. 6D). Chk1 depletion (Fig. 6A, Fig. S2 C) or inhibition (Fig. 6B) had an additive cytotoxic effect on tetraploid cells in vitro, in short-term assays. Treatment of tetraploid HCT116 tumors that had been established in xenotransplanted immunodeficient mice with a subtoxic dose of UCN-01 had no growth-inhibitory effect (Fig. 6E). However, the combination of cisplatin plus UCN-01 had a synergistic anti-cancer effect, which was particularly pronounced for tetraploid tumors (Fig. 6F). Based on these observations, we decided to explore the effect of cisplatin, Chk1 inhibition and the combination of both on the transcriptome of diploid and tetraploid colon cancer (HCT116) cells. The number of cisplatin-modulated genes showing a statistically relevant altered expression (p value<10^{-5}) was higher among diploid than among tetraploid cells (Fig. 7A,B), correlating with the higher susceptibility of diploid cells to cisplatin-induced killing (Fig. 6D). In contrast, the number of genes modulated by Chk1 inhibition was significantly higher among tetraploid (152 genes) than among diploid cells (20 genes), with only six genes that were modulated in both diploid and tetraploid cells (Fig. 7A,B), again correlating with the enhanced killing of tetraploid cells by Chk1 inhibitors. The combination of cisplatin and Chk1 inhibition modified a large pool of transcripts that were common to tetraploid and diploid cells, with a higher number of tetraploid- than diploid- specific transcripts (Fig. 7A,B), in correlation with the particularly dramatic effects of the combined therapeutic regimen on tetraploid cells in vivo (Fig. 6F).

Mechanisms of the cytotoxic effects of Chk1 inhibition

Close inspection of the microarray data led us to the discovery that Chk1 inhibition caused the modulation of a particularly elevated percentage (12.3%) of p53 target genes in tetraploid cells (Fig. 7A,B), correlating with the higher susceptibility of diploid cells to cisplatin-induced killing (Fig. 6D). In contrast, the number of genes modulated by Chk1 inhibition was significantly higher among tetraploid (152 genes) than among diploid cells (20 genes), with only six genes that were modulated in both diploid and tetraploid cells (Fig. 7A,B), again correlating with the enhanced killing of tetraploid cells by Chk1 inhibitors. The combination of cisplatin and Chk1 inhibition modified a large pool of transcripts that were common to tetraploid and diploid cells, with a higher number of tetraploid- than diploid- specific transcripts (Fig. 7A,B), in correlation with the particularly dramatic effects of the combined therapeutic regimen on tetraploid cells in vivo (Fig. 6F).
with a specific siRNA. p53 knockdown strongly reduced the cytotoxic effect of Chk1 depletion (Fig. 8A). Similarly, tetraploid derivatives of p532/2 HCT116 cells, generated as previously described [8], died significantly less than the p53 proficient tetraploid cells in response to the knockdown of Chk1 (Fig. 8B) or that of Bub1, BubR1, Mad2 or AuroraB (Fig. 8C). In each case, the inhibition of p53 strongly attenuated the cytotoxic effects of cisplatin and/or SAC inhibition.

Next, we downregulated a series of p53 target genes that were strongly induced by Chk1 inhibition in tetraploid cells (Table S1). Knockdown of the BH3-only protein Puma/BBC3, of the pro-apoptotic transcription factor ATF3 [36] (Fig. 8D) attenuated the cytotoxic effect of Chk1 inhibition in tetraploid cells, while the depletion of villin 3 (ezrin), spermidine/spermine N1-acetytransferase (SSAT) or of the essential autophagy gene Atg12 had no such effect (Fig. 8D). These results suggested that the Bcl-2 protein family dictates the fate of Chk1-inhibited tetraploid cells. Accordingly, knockdown of Puma/BBC3 and of the pro-apoptotic multi-domain Bcl-2 family proteins Bax and Bak were as efficient in inhibiting Chk1 depletion-induced cell death as was the downregulation of p53 and the p53 associated protein p53BP1 (Fig. 8E). These data could be corroborated at the genetic level. Tetraploid cells derived from parental Bax2/2 HCT116, generated as previously described [8], cells failed to die in response to Chk1 depletion (Fig. 8F). Moreover, knockdown of the endogenous Bax/Bak antagonists Bcl-2 or Bcl-XL sensitized tetraploid cells to Chk1 inhibition (Fig. 8E). Altogether, these results indicate that Chk1 inhibition kills tetraploid cells via the
Figure 5. Apoptosis induction by Chk1 or SAC inhibition. A. Chk1 inhibition by a dominant-negative (DN) Chk1 mutant. Diploid or tetraploid HCT116 cells were transfected with vector only (Co) or vectors encoding wild type (WT) or DN Chk1 or Chk2, together with a DsRed-encoding construct. 48 h later, cells were stained with DiOC6(3) and the frequency of DiOC6(3)low cells was determined among the transfected (dsRed+) population. B-F. Chk1 inhibition by pharmacological agents. HCT116 cells were cultured for 48 h in the presence of the indicated concentrations of UCN-01 (B,D) or SD1825 (C,D) and the frequency of dead and dying cells was measured by co-staining with DiOC6(3) and PI (as in Fig. 3A). Alternatively, cells cultured on polylysine slides were stained for the simultaneous immunofluorescence detection of mitochondrial cytochrome c (Cyt c) release and caspase-3 activation (Casp-3a). Representative microfluorographs are shown in D and the frequency of cells showing diffuse Cyt c staining and caspase-3 activation are scored in E. Finally, phosphatidylserine exposure was measured in diploid and tetraploid RKO cells by annexin V-FITC staining (F). Asterisks denote significant (p < 0.01) effects of Chk1 inhibition. G, H. Preferential mortality of tetraploid cells subjected to SAC inhibition. Diploid or tetraploid cells were depleted from the indicated SAC proteins. Forty-eight hours later, apoptotic events were scored by measuring the frequency of $\Delta \Psi_m$ (with DiOC6(3)) and viability (with PI) (G) or sub-G1 cells (H). Columns represent the average of three independent experiments ± SEM.

doi:10.1371/journal.pone.0001337.g005
Figure 6. Combined effects of Chk1 inhibition and cisplatin on tetraploid tumor cells in vitro and in vivo. A. Cytotoxic effects of Chk1 depletion in combination with cisplatin. Diploid (D) and tetraploid (T) HCT116 cells were knocked down for Chk1 (or transfected with control siRNA SCR) for 24 h and then cultured in absence or presence of cisplatin (20 μM) for further 48 h. Finally, the frequency of dying (DiOC6(3)low PI”) or dead (DiOC6(3)low PI’) cells was monitored by DiOC6(3)/PI staining. B. Cell killing by pharmacological inhibition of Chk1 plus cisplatin. Cells were cultured with cisplatin (20 μM), UCN-01 (500 nM) and/or SD1825 (500 nM) for 48 h, and dead and dying cells were determined as in A. C–E. Combined effects of Chk1 inhibition and cisplatin on tetraploid tumors established in vivo. Diploid or tetraploid HCT116 tumors were established in vivo and their growth was monitored continuously from day 18 (when tumors measured 125 to 250 mm3), when animals were injected with PBS alone (controls in C), cisplatin (D), UCN-01 (E), or with a combination of both (F). Asterisks indicate significant differences between diploid and tetraploid cells (p<0.05, unpaired Student t test). The results shown in Fig. 6C–E are representative for three different experiments.

doi:10.1371/journal.pone.0001337.g006
activation of a p53-dependent pathway that elicits mitochondrial membrane permeabilization through the induction of Puma, which in turn acts on its mitochondrial receptors Bax and Bak.

**DISCUSSION**

In the present study, we show that inhibition of Chk1 by small interfering RNAs, dominant-negative mutant Chk1, or pharmacological compounds is particularly toxic on tetraploid tumor cells that otherwise are relatively resistant against genotoxic agents. The mechanism accounting for the preferential killing of tetraploid cells appears to involve the abolition of the spindle assembly checkpoint (SAC), premature entry in mitosis, failed and catastrophic mitotic events, as well as p53 activation, transcription of pro-apoptotic p53 target genes including the BH3 only protein Puma and induction of the mitochondrial pathway of apoptosis.

Although this sequence of events is well documented in this paper, it is at variance with previous knowledge on cell death induction by Chk1 inhibition. First, Chk1 activation reportedly causes the phosphorylation of p53, resulting in its stabilization and its transcriptional activation [37]. On the contrary, here we show that the inhibition of Chk1 can activate p53, as indicated by an increased p53 phosphorylation and an increased transcription of p53 target genes. Second, Chk1 inhibition by UCN-01 or other chemical Chk1 inhibitors has been shown to sensitize preferentially p53-deficient cells [38–40]. In contrast with this notion, we show here that, at least for tetraploid cells, p53 activation is required for the cytotoxic effect of Chk1 inhibition. Thus, inhibition of p53 (chemically or genetically, by knockdown or knockout) strongly reduced cell killing by Chk1 inhibition or depletion.

What may be the mechanism through which Chk1 inhibition is particularly toxic for tetraploid cells? Reportedly, Chk1 is required

---

Figure 7. Microarray analyses of the transcriptome of diploid (D) and tetraploid (T) HCT116 cells treated with cisplatin, Chk1 inhibitor or the combination of both. A. Hierarchical cluster analysis of 1411 gene expression profiles in the 6 experimental samples is shown. Each row represents the combination of two dye-swap experiments compared to untreated control cells and each column represents a single gene. Red and green colors indicate an increase and a decrease, respectively, in the expression of genes as compared to unstimulated control cells. B. Overview of the modification of gene expression by cisplatin and Chk1 inhibition in diploid and tetraploid cells (p value<10^-5).

doi:10.1371/journal.pone.0001337.g007
Figure 8. Involvement of p53 and Bcl-2 family proteins in apoptosis induction by Chk1 inhibition. A. Effect of p53 knockdown. Diploid or tetraploid HCT116 cells were transfected with control siRNA (SCR), a p53-specific siRNA, and/or Chk1-depleting siRNA and cultured in the presence of absence of cisplatin during the last 24 hours of the 72-hour experiment. Then, cells were stained with DiOC6(3)/PI.

B, C. Effect of p53 knockout. Tetraploid HCT116 cells generated on a wild type (WT) or p53 knockout (p53^−/−) background were treated with the indicated combination of Chk1-depleting siRNA and/or cisplatin (B) or were depleted from SAC proteins (C), followed by determination the frequency of dying (DiOC6(3)^low PI^−) or dead (DiOC6(3)^low PI^+). Results (X±SEM, n = 3) are representative of three independent determinations. Asterisks indicate a significant protection by p53 deletion.

D. Contribution of p53 target genes to Chk1 depletion-induced apoptosis. Tetraploid HCT116 cells were transfected with the indicated siRNAs and the frequency of cell death was determined by DiOC6(3)/PI staining.

E. Contribution of p53 and pro-apoptotic proteins of Bcl-2 family to the death of HCT116 cells induced by Chk1 depletion. Tetraploid HCT116 cells were subjected to the siRNA-mediated downregulation of Chk1 alone or together with the indicated gene products, followed by measurement of cell viability with a tetrazolium reduction assay. Negative values indicate sensitization to the cytoxicity of Chk1 depletion while positive values indicate protective effects (X±SEM, n = 3).

F. Effect of Bax knockout. Tetraploid HCT116 cells generated on a wild type (WT) or Bax knockout (Bax^−/−) background were subjected to Chk1 inhibition, followed by determination of the frequency of dead and dying cells 48 h later. Results (X±SEM) are representative of three independent determinations.

doi:10.1371/journal.pone.0001337.g008
for optimal progression of replication forks during normal S phase of vertebrate cells [41] and avoids the accumulation of DNA breaks at fragile sites [42]. On theoretical grounds, the replication of a tetraploid set of chromosomes may be particularly vulnerable to perturbations, which ultimately results in delayed or incomplete DNA replication followed by premature and catastrophic mitosis. Chk1 depletion can favor the premature activation of the Cdk1/cyclin B1 complex [43], before the completion of the S phase, which leads to mitotic defects with chromosome misalignment during metaphase, chromosome lagging during anaphase, and kinetochore defects within the regions of misaligned/lagging chromosomes [44]. Hence, Chk1 depletion may amplify the natural tendency of tetraploid cells to die during or shortly after mitosis.

There is an alternative and additional explanation for the preferential toxicity of Chk1 inhibition on tetraploid cells that is supported by our data. Chk1 is required for spindle checkpoint function, both in normal and in taxol-treated cells [45]. As shown here, tetraploid cells have an intrinsic propensity to undergo mitotic catastrophe although they have an intact spindle assembly checkpoint (SAC) and even tend to spontaneously activate SAC. Chk1 depletion compromises the spindle checkpoint by negatively affecting the Aurora-B-dependent recruitment of BubR1 to kinetochores [45]. We have confirmed this finding, showing that Chk1 inhibition prevents the recruitment of both BubR1 and Bub1 to the centromeres of tetraploid cells during the prometaphase or aberrant metaphases. Moreover, we have found that inhibition of SAC by depletion of essential SAC proteins (such as Bub1, BubR1 or Mad2) or inhibition of Aurora-B had similar effects as Chk1 inhibition, namely a selective toxicity for tetraploid as compared to diploid cells. The abolition of SAC killed tetraploid cells through the activation of p53, exactly as this has been observed for Chk1 inhibition. Chk1 inhibition caused the abrogation of SAC both in diploid and tetraploid cell lines; nevertheless, SAC is more frequently activated in untreated tetraploid cells, correlating with an elevated frequency of abnormal mitoses. Hence, it appears plausible that Chk1 inhibition kills tetraploid cells through its capacity to abrogate SAC and because tetraploids rely more heavily on an intact SAC than diploid cells.

Chk1 inhibitors including UCN-01 are being introduced into clinical trials [24] in combination with genotoxic agents such as cytarabine (for the treatment of acute myeloid leukemia) [46] or cisplatin (for the treatment of advanced solid tumors) [47], and proof has been obtained that UCN-01 can actually inhibit Chk1 in vitro, in tumor cells [46], although the inhibitor may act on other kinases including Chk2 and PDK1 as well, at least in vitro. As shown here, Chk1 inhibition by UCN-01 sensitizes tetraploid cells to cisplatin-induced cell death, rendering otherwise chemoresistant tetraploid tumors amenable to treatment. In vivo, in a model of xenotransplanted human tumors. The mechanism through which Chk1 inhibition (by UCN-01 or by two distinct specific siRNAs) can restore the cisplatin sensitivity of tetraploid cells is elusive. Based on the microarray data and cytotoxic effects, it appears that diploid cells are relatively refractory to the apoptosis-inducing and to the transcriptome-modifying effects of Chk1 inhibition (as compared to tetraploid cells), while tetraploid cells are relatively resistant against the cytoidal and transcriptional effect of cisplatin (as compared to diploid cells). The combination of both cisplatin and Chk1 inhibition had very similar effects on diploid and tetraploid cells in thus far that it provoked cell death at a substantially similar level and regulated a largely overlapping panel of genes at the transcriptional level. Apparently, p53 target genes are particularly important in mediating the combined lethal effect of cisplatin and Chk1 inhibition, both in diploid and tetraploid cells. The DNA damage-elicted kinase ATR is elicited by cisplatin [48,49] and may participate in the activation of Chk1, which in turn mediates the cisplatin-induced cell cycle arrest [50,51]. Hence, inhibition of Chk1 may subvert a DNA damage-elicted cell cycle checkpoint, thereby preventing DNA repair and favoring an apoptotic response.

The challenge for future studies will be to determine whether other specific Chk1 inhibitors can overcome chemoresistance of tumor cells in vivo, in suitable preclinical models as well as in clinical trials. It will be particularly interesting to determine whether Chk1 inhibitors can be used for the treatment or even for the prophylaxis of polyplloidization-associated neoplasias.

**MATERIALS AND METHODS**

**Cell lines, culture, transfection and siRNA**

Tetraploid cells were generated from diploid WT, p53−/−, Bax−/− (gift from Bert Vogelstein) HCT116 and RKO diploid precursor as previously described in [8,35]. Diploid or tetraploid HCT116 cells were grown in McCoy’s 5A medium supplemented with 10% FCS. RKO clones transfected with the cDNA encoding H2B-GFP were cultured in the presence of blasticidin (20 μg/ml). All media and supplements for cell culture were purchased from Gibco-Invitrogen (Carlsbad, USA). For each experiment at least three clones diploid and tetraploid were used. Subconfluent cultures were cultured in the absence or in the presence of cisplatin (20 μM, Sigma-Aldrich, St. Louis, USA) and/or Chk1 inhibitors (UCN-01 from the NCI, USA; SD1825, from Servier, Neuilly-sur-Seine, France, see Fig. S4, IC50 for recombinant Chk1 in vitro: 29 nM) at indicated concentrations for 24–48 hours, in the presence or in the absence of the pan-caspase inhibitor Z-valine-alanine-aspartate-fluoromethyl ketone (Z-VAD-fmk, 100 μM) or of the p53 inhibitor cyclic pifithrin-α (20 μM). Cells were transfected with pRe/CMV containing human wild-type p53 (WT) or mutant (H175)p53 (gift of T. Soussi, Institut Curie, Paris, France) under the control of the cytomegalovirus (CMV) promoter [52]. Alternatively, cells were transfected with CMV-driven expression plasmids containing WT or DN Chk1 (kinase dead, gift from K.K. Khanna) [53], WT or DN Chk2 [54], or a p53-inducible green fluorescence protein (GFP) plasmid (gift from K. Wiman, Karolinska Cancer Center, Stockholm, Sweden) [55]. Transfections were performed by adding lipofectamine™ 2000 (Invitrogen) complexed with plasmid (final concentration: 1 μg/ml) 24 hours before the addition of cyclic pifithrin-α (15 μM; Sigma-Aldrich) or cisplatin (20 μM; Sigma-Aldrich). In some experiments, transfections were performed in the presence of pΔRed2 vector (0.2 μg/ml; Clontech, Palo Alto, USA) to identify transfected cells. After additional 48 hours, cells were subjected to cytofluorometric analysis of viability.

The knock-down of Atg12, ATF3, Aurora B, Bad, Bax a, Bcl-2, Bcl-XL, Bid, Bub1, BubR1, Chk1, Chk2, Mad2, p53, p53BP1, PUMA, sperrmidine/sperrmine N1-acetyltransferase (SSAT), Survivin, VDAC1, villin 3 (ezrin), was performed with siRNAs purchased from Sigma-Prologi (The Woodlands, USA, siRNA sequences in Table S2); the down-regulation of Bak and Bax was performed with siRNAs (Hs_BAK_5, Hs_BAX_5 and Hs_BAX_10 HP Validated siRNAs, respectively) purchased from Qiagen (Hilden, Germany). As a control, a siRNA specific for emerin [56] as well as unselected control siRNAs (scramble, SCR) were used. Cells were cultured in 12-well plates and transfected at 30–40% confluence by adding HiPerFect (Qiagen, Hilden, Germany) complexed with siRNA (final concentration: 20nM) as described previously [57]. 72 h later, the efficiency of transfection was determined by immunoblot.
Measurement of cell viability with a tetrazolium reduction assay

3.5×10^5 HCT116 cells were seeded in 100 μl of McCoy’s 5A medium in 96-well plates and transplanted after 24 h, as follows. 2.5 pmol of each siRNA plus 2.5 pmol of Chk1-specific siRNA or control siRNA (SCR), dissolved in 10 μl of serum-free, antibiotic-free, DMEM:F12 (1:1) with L-glutamine but no phenol red were mixed with 0.5 μl of HiPerFect transfection reagent (Qiagen) dissolved in 10 μl of the same medium and let stand at room temperature for 30 min. Thereafter, transfection complexes (20 μl) were added to the cultures. Transfected cells were maintained for 48 h prior to cell viability assays based on the cleavage of the tetrazolium salt WST-1 (Roche Diagnostics, Germany).

Staining of live cells, immunofluorescence and videomicroscopy

For the simultaneous assessment of mitochondrial apoptosis and plasma membrane permeabilization, live cells were stained with 3,3’-dihexiloxalocarbocyanine iodide or tetramethylrhodamine methyster (DiOC6(3) 40 nM or TMRE 150 nM, emitting in green or in red respectively; Molecular Probes-Invitrogen) which measure Δψm and propidium iodide (PI, 2 μg/ml, Sigma-Aldrich) or 4',6-diamidino-2-phenylindole (DAPI, 10 μM, Molecular Probes-Invitrogen), vital dyes that incorporate only into dead cells), for 30 min at 37°C [56]. Exposure of phosphatidylserine (PS) was evaluated using annexin V-FTTC (Molecular Probes, Invitrogen). For simultaneous measurement of DNA content and Histone H3 phosphorylation, cells were fixed with ethanol (70% v:v), permeabilized with tween (0.25% v:v) and stained with DAPI (10 μM, Molecular Probes-Invitrogen) and a rabbit antisera specific for Histone H3 phosphorylated (Upstate, Lake Placid, USA). Cyto-fluorometric analyses were performed on a FACS Vantage (Becton Dickinson, San Jose, USA) equipped with a 70 μm nozzle. Data were statistically evaluated using Cell Quest software (Becton Dickinson).

Alternatively, for fluorescence microscopy, cells were fixed with paraformaldeyhde (4% v:v) then stained with rabbit antisera specific for p53 phosphorylated on serine 15 (Cell Signaling Technology Inc., Danvers, USA), and for activated caspase-3 (Casp-3a, Cell Signaling Technology Inc.) or with mouse antisera specific for cytochrome c (cyt c, BD Biosciences, San Jose, USA), β-tubulin, or γ-tubulin (both from Sigma-Aldrich) [7,59].

To detect Bub1, BubR1 and CENP-B, cells were fixed in 4% (w/v) paraformaldehyde in PIPES buffer (80 mM PIPES, 5 mM EGTA, 2 mM MgCl2) and co-immunostained with antibodies that recognize Bub1 (rabbit polyclonal IgG, Chemicon International, Temecula, USA), BubR1 (mouse monoclonal antibody, BD Biosciences) and CENP-B (mouse monoclonal IgG, Santa Cruz Biotechnology, San Jose, USA) [Vitale et al., 2007].

After the incubation with the primary antibody, slides were incubated with goat anti-rabbit or anti-mouse IgG conjugated to Alexa 488 or to Alexa 488 fluorochrome (Molecular Probes-Invitrogen).

Chromatin was stained with Hoechst 33342 (2 μM, Molecular Probes-Invitrogen). RKO cells expressing histone H2B-GFP were cultured in the 35mm glass bottom culture dishes (MatTek Corporation, Ashland, USA), maintained at a constant temperature of 37°C in an atmosphere with 5% CO2, and were subjected to pulsed observations using an LSM 510 laser-scanning confocal microscope (Zeiss, Oberkochen, Germany).

Quantitation of protein expression

Protein samples were prepared from HCT116 or RKO cells in lysis buffer. Aliquots of protein extracts (50 μg/lane) were subjected to immunoblots using antibodies specific for Bcl-2 (Santa Cruz Biotechnology), Bub1 (Chemicon International), CENP-B (Santa Cruz Biotechnology), BubR1 (BD Biosciences), Chk1 (Santa Cruz Biotechnology), Chk2 (Upstate), Mad2 (Santa Cruz Biotechnology), VDAC (anti-porin 31kL, Calbiochem International, Temecula, USA) and GAPDH (Chemicon, CA) monitored as loading control.

Microarray analyses

We used Agilent long (60bp) oligonucleotide microarrays and the dual color analysis method in which probes from specimens and from the reference are differentially labeled with Cyanine 5 and Cyanine 3 as described previously (Castedo et al, 2006). We performed a set of 6 dye swap experiments to compare RNAs obtained, in each case, from tetraploid and diploid HCT116 cell lines cultured in the presence of cisplatin, UCN-01 and a combination of both. In each experiment, the reference was RNAs from cell lines without treatment. From each of the 6 combined experiments, signatures (list of accession numbers) at p-value of 10^-5 are extracted and annotated with updated databases as Ingenuity Pathways Analysis program (by a query of genes for which p33 directly interact with DNA, Ingenuity, Mountain View, USA, http://www.ingenuity.com/products/pathways_analysis.html).

In vivo model

Athymic nu/nu six-week-old female mice (IGR animal facility) were inoculated s.c in 200 μl of PBS with 3×10^6 diploid or tetraploid HCT116 cells into the lower flank as previously described [60]. When tumors reached 125 mm^3, mice received i.p. either 200 μl of PBS, 5mg/kg of cisplatin three times a week during 3 weeks, UCN-01 (7.5 mg/kg/daily) for 5 consecutive days or a combination of cisplatin plus UCN-01. Tumor growth was evaluated twice a week using a caliper. The mean of the tumor volume at each point was normalized in each group to the mean volume measured at the first injection. All animals were maintained in specific pathogen-free conditions and all experiments followed the FELASA guidelines.

SUPPORITING INFORMATION

Table S1

Found at: doi:10.1371/journal.pone.0001337.s001 (2.69 MB DOC)

Table S2

Found at: doi:10.1371/journal.pone.0001337.s002 (0.07 MB DOC)

Figure S1

Found at: doi:10.1371/journal.pone.0001337.s003 (2.88 MB TIF)

Figure S2

Found at: doi:10.1371/journal.pone.0001337.s004 (2.82 MB TIF)
Biotechnology, respectively. Equal loading was determined with ProSci Incorporated, Santa Cruz Biotechnology, and Upstate rabbit antibodies specific for Puma, ATF3 and Bax were from transfection of tetraploid HCT116 cells with control scrambled and Bax was determined by immunoblot, 48 hours after treated by siRNAs targeting emerin (as a negative control), tetraploid RKO cells. Diploid or tetraploid RKO cells were combined effects of Chk1 inhibition and cisplatin (20 μM) on tetraploid RKO cells. Diploid or tetraploid RKO cells were treated by siRNAs targeting emerin (as a negative control), VDAC1 (as a positive control of apoptosis inhibition), Chk1 or Chk2, followed by staining with TMRM to measure ΔΨm dissipation

Figure S3 The efficacy of the siRNAs specific for Puma, ATF3 and Bax was determined by immunoblot, 48 hours after transfection of tetraploid HCT116 cells with control scrambled (SCR) siRNA or the indicated specific siRNAs. The polyclonal rabbit antibodies specific for Puma, ATF3 and Bax were from ProSci Incorporated, Santa Cruz Biotechnology, and Upstate Biotechnology, respectively. Equal loading was determined with anti-actin antibody (monoclonal mouse IgG1 from AbCys).

Figure S4 Chemical structure of SD 1825 and its IC50 for recombinant Chk1

Video S1 Abnormal mitoses in untreated tetraploid RKO cells expressing histone H2B-GFP. The video shows an example of a cell that undergoes an apparently normal mitosis, followed by near-to-complete karyokinesis, furrow regression and formation of one single binucleate cell, as well as a cell arrested in metaphase

Video S2 Abnormal mitosis in untreated tetraploid RKO cells expressing histone H2B-GFP. The video exemplifies an aborted cell division leading to the formation of a single daughter cell

Video S3 Normal mitosis in Chk1 depleted tetraploid RKO cells expressing histone H2B-GFP. Selected pictures are shown in Fig. 2A, 0

Video S4 Delayed mitosis in Chk1 depleted tetraploid RKO cells expressing histone H2B-GFP. Selected pictures are shown in Fig. 2A, 1

Video S5 Delayed mitosis leading to apoptosis of both daughter cells in Chk1 depleted tetraploid RKO cells expressing histone H2B-GFP. Note that the final result of the process is the generation of one single binucleated cell. Selected pictures are shown in Fig. 2A, 2

Video S6 Aberrant mitosis with an abnormal metaphase plate in Chk1 depleted tetraploid RKO cells expressing histone H2B-GFP. Normal mitosis in Chk1 depleted tetraploid RKO cells expressing histone H2B-GFP. Selected pictures are shown in Fig. 2A, 3

REFERENCES

1. Shi Q, King RW (2005) Chromosome nondisjunction yields tetraploid rather than aneuploid cells in human cell lines. Nature 437: 1038–1042.
2. Duelli D, Lazebnik Y (2003) Cell fusion: a hidden enemy? Cancer Cell 3: 445–448.
3. Ogle BM, Cascalho M, Platt JL (2005) Biological implications of cell fusion. Nat Rev Mol Cell Biol 6: 567–575.
4. Storchova Z, Pellman D (2004) From polyplody to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol 5: 45–54.
5. Fujisawa T, Bandi M, Nitta M, Ivanova IV, Bronson RT, et al. (2005) Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 437: 1043–1047.
6. Margolis RL (2005) Tetraploidy and tumor development. Cancer Cell 8: 333–354.
7. Castedo M, Roumier T, Blanco J, Ferri KF, Barretina J, et al. (2004) Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 23: 4070–4080.
8. Castedo M, Coquelle A, Vivet S, Vitale I, Kauffmann A, et al. (2006) Apoptosis in tetraploid cancer cells. EMBO J 22: 2258–2265.
9. Andreassen PR, Lohez OD, Lacroix FB, Margolis RL (2001) Tetraploid state induces p53-dependent arrest of nontransformed mammalian cells in G1. Mol Biol Cell 12: 1315–1320.
10. Tsouhlaraki K, Lapin V, Bakal G, Okada H, Brown L, et al. (2005) Chk2 regulates anoikis, cell cycling, and cell death in a p53-dependent manner. Cancer Res 65: 6683–6691.
11. Sugimoto M, Greenslade A, Sherr CJ (2006) Hsf1, a p53-responsive gene, regulates maintenance of the G2 phase checkpoint induced by DNA damage. Mol Cell Biol 26: 302–312.
12. Aylon Y, Michael D, Shmueli A, Yalutna N, Nojima H, et al. (2006) A positive feedback loop between the p53 and Lat2 tumor suppressors prevents tetraploidization. Genes Dev 20: 2687–2700.
13. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema RH, et al. (2004) Cell death by mitotic catastrophe: a molecular definition. Oncogene 23: 2825–2837.
14. Waldman T, Lengauer C, Kinzler KW, Vogelstein B (1996) Uncoupling of S phase and mitosis induced by anti-cancer agents in cells lacking p21. Nature 381: 713–716.
15. Tighe A, Johnson VL, Taylor SS (2004) Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosomal instability. J Cell Sci 117: 6339–6353.
16. Wang X, Zhou XY, Qiao W, Tominaga Y, Ouchi M, et al. (2006) Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation. Oncogene 25: 7148–7158.
17. Incassati A, Patel D, McCance DJ (2006) Induction of tetraploidy through loss of p21. Nature 437: 1038–1042.
18. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434: 864–870.

ACKNOWLEDGMENTS

We thank Christophe Chamot and Tristan Pirot from the Institute Jacques Monod Imaging Facilities for help in video microscopy. We thank Abdelali Jalil from the Institut Gustave Roussy for his excellent technical assistance. We thank the National Institute for Cancer (NCI, Bethesda, USA) for providing UCN-01.

Author Contributions

Conceived and designed the experiments: GK IV LG MC. Performed the experiments: IV LG SV LN PD LS KO VL MC. Analyzed the data: GK IV LG SV LN PD LS KO VL MC. Contributed reagents/materials/analysis tools: MP RG. Wrote the paper: GK IV MC.
19. Gorgoulis VG, Vassilou LV, Karakaidos P, Zacharatos P, Kotsinas A, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434: 907–913.

20. Neveu-Lemaire H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25: 5912–5919.

21. Zhou BB, Sausville EA (2003) Drug discovery targeting Chk1 and Chk2 kinases. Prog Cell Cycle Res 5: 413–421.

22. Suljasevic RG, Sorenson CS, Nylonstedt J, Lukas C, Lukas J, et al. (2004) Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res 64: 9035–9040.

23. Furuta T, Hayward RL, Meng LH, Takemura H, Amre GJ, et al. (2006) p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxysteroidal. Oncogene 25: 2139–2149.

24. Tao ZF, Lin NH (2006) Chk1 inhibitors for novel cancer treatment. Anticancer Agents Med Chem 6: 377–388.

25. Pawelek JM (2005) Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol 6: 988–993.

26. Duelli DM, Hearin S, Myers MP, Laeznik Y (2003) A primate virus generates transformed human cells by fusion. J Cell Biol 171: 493–503.

27. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, et al. (2004) The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 64: 7629–7633.

28. Heselmeyer K, Schrock E, du Maurier S, Blegen H, Shah K, et al. (1996) Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acad Sci U S A 93: 479–484.

29. Bjelkengren K, Lundgren J, Olofsson J (1983) Single-cell DNA measurement in hyperplastic, dysplastic and carcinomatous laryngeal epithelia, with special reference to the occurrence of hypertetraploid cell nuclei. Anal Quant Cytol 5: 184–188.

30. Cuvelier CA, Morson BC, Roels HJ (1987) The DNA content in cancer and cancerous lesions of the uterine cervix by DNA measurements on tissue sections. Anal Quant Cytol Histol 7: 320–326.

31. Barres DR, Duhr MA, Boivin YA (1985) Discrimination between precancerous and cancerous lesions of the uterine cervix. Histopathology 11: 927–939.

32. Van Dyke DL, Worsham MJ, Benninger MS, Krause CJ, Baker SR, et al. (1994) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Proc Natl Acad Sci U S A 100: 15065–15070.

33. Zermiti Y, Mouhammad S, Stergiou L, Besse B, Galluzzi L, et al. (2007) Non-apoptotic role for Apaf-1 in the DNA damage response. Mol Cell in press.

34. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signalling through the p38MAPK/ MK2 pathway for survival after DNA damage. Cancer Cell 11: 175–189.

35. Stevens C, Smith L, La Thangue NB (2003) Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5: 401–409.

36. Gatei M, Sloper K, Sorensen C, Syljuasen R, Falck J, et al. (2003) Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 to Ser-317 in response to ionizing radiation. J Biol Chem 278: 14806–14811.

37. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signalling through the p38MAPK/ MK2 pathway for survival after DNA damage. Cancer Cell 11: 175–189.

38. Asher G, Lomen J, Tsevekov P, Reiss V, Sachs L, et al. (2003) p38 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinoine oxidoreductase 1. Proc Natl Acad Sci U S A 100: 15065–15070.

39. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini JL, et al. (2003) Telomere dysfunction induces cell death in a mitochondondependent fashion. J Exp Med 197: 1323–1334.

40. Chen Z, Xiao Z, Guo WZ, Xue J, Bui MH, et al. (2006) Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 119: 2784–2794.

41. Tada Y, Mato-Mendoza A, Zachos G, Gillespie DA, Jackson DA, et al. (2006) Chk1 requirement for high global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 26: 3319–3326.

42. Anand A, Bell FG, Kwok PY, workshop on human xenograft models for cancer studies. Cancer Res 64: 1950–1951.

43. Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, et al. (2001) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3: 10–16.

44. Brown GC, Masliah D, Sorenson C, Safford K, Ewing R, et al. (2003) Reiter cytoskeletal abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 9: 192–206.

45. Buhmeida A, Backman H, Collan Y (2002) DNA cytometry in diagnostic cytology of the prostate gland. Anticancer Res 22: 2397–2402.

46. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, et al. (2004) High global rates of replication fork progression during normal vertebrate S phase. Mol Cell Biol 26: 3319–3326.

47. Lara PN Jr, Mack PC, Snydell T, Frankel P, Longmate J, et al. (2005) The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 11: 4444–4450.

48. Zhao H, Pisvica-Worms H (2001) ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21: 4129–4139.

49. Damia G, Filiberti L, Vikhanskaya F, Carrassa L, Taya Y, et al. (2001) Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3: 10–16.

50. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54–61.

51. Reinhardt HC, Asl miners AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signalling through the p38MAPK/ MK2 pathway for survival after DNA damage. Cancer Cell 11: 175–189.

52. Asher G, Lomen J, Tsevekov P, Reiss V, Sachs L, et al. (2003) p38 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinoine oxidoreductase 1. Proc Natl Acad Sci U S A 100: 15065–15070.

53. Gatzi M, Sloper K, Sorensen C, Syljuasen R, Falck J, et al. (2003) Ataxia telangiectasia-mutated (ATM) and NBS1-dependent phosphorylation of Chk1 on Ser-317 in response to ionizing radiation. J Biol Chem 278: 14806–14811.

54. Stevens C, Smith L, La Thangue NB (2003) Chk2 activates E2F-1 in response to DNA damage. Nat Cell Biol 5: 401–409.

55. Byea P, Andreau K, Poncet D, Zamzami N, Perfettini JL, et al. (2003) Dynasom membrane permeabilization induces cell death in a mitochondondependent fashion. J Exp Med 197: 1523–1534.

56. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494–498.

57. Criollo A, Galluzzi L, Chiara Maiuri M, Tasdemir E, Lavandero S, et al. (2007) Chk1 leads to premature activation of Cdc2-cyclin B and mitotic catastrophe. J Biol Chem 282: 39246–39252.

58. Castedo M, Coquelle A, Vitale I, Vivet S, Mouhammad S, et al. (2006) Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis. Oncogene 25: 4129–4139.

59. Perfettini JL, Castedo M, Roumier T, Andreau K, Nardacci R, et al. (2005) The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res 11: 4444–4450.

60. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, et al. (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54–61.